Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C, Valenzuela B, Fernández Teruel C, González-Sales M, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ. Pérez-Ruixo C, et al. Cancer Chemother Pharmacol. 2012 Jan;69(1):15-24. doi: 10.1007/s00280-011-1644-6. Epub 2011 May 18. Cancer Chemother Pharmacol. 2012. PMID: 21590449 Clinical Trial.
Plitidepsin has a safe cardiac profile: a comprehensive analysis.
Soto-Matos A, Szyldergemajn S, Extremera S, Miguel-Lillo B, Alfaro V, Coronado C, Lardelli P, Roy E, Corrado CS, Kahatt C. Soto-Matos A, et al. Mar Drugs. 2011;9(6):1007-1023. doi: 10.3390/md9061007. Epub 2011 Jun 9. Mar Drugs. 2011. PMID: 21747745 Free PMC article. Clinical Trial.
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Candelaria M, Gonzalez D, Fernández Gómez FJ, Paravisini A, Del Campo García A, Pérez L, Miguel-Lillo B, Millán S. Candelaria M, et al. Among authors: miguel lillo b. Cancer Chemother Pharmacol. 2018 Mar;81(3):515-527. doi: 10.1007/s00280-018-3524-9. Epub 2018 Jan 24. Cancer Chemother Pharmacol. 2018. PMID: 29362903 Clinical Trial.
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C, Tabernero J, Coronado C, García M, Soto Matos-Pita A, Miguel-Lillo B, Cullell-Young M, Iglesias Dios JL, Paz-Ares L. Salazar R, et al. Among authors: miguel lillo b. Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83. doi: 10.1007/s00280-013-2170-5. Epub 2013 May 5. Cancer Chemother Pharmacol. 2013. PMID: 23645288 Clinical Trial.
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial).
Petty R, Anthoney A, Metges JP, Alsina M, Gonçalves A, Brown J, Montagut C, Gunzer K, Laus G, Iglesias Dios JL, Miguel-Lillo B, Bohan P, Salazar R. Petty R, et al. Among authors: miguel lillo b. Cancer Chemother Pharmacol. 2016 Apr;77(4):819-27. doi: 10.1007/s00280-016-2991-0. Epub 2016 Mar 10. Cancer Chemother Pharmacol. 2016. PMID: 26964995 Clinical Trial.
Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.
van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AHM, Schellens JHM, Beijnen JH. van Andel L, et al. Among authors: miguel lillo b. Invest New Drugs. 2017 Oct;35(5):589-598. doi: 10.1007/s10637-017-0432-5. Epub 2017 Jan 23. Invest New Drugs. 2017. PMID: 28111728 Clinical Trial.
14 results